Armistice Capital LLC recently announced the acquisition of new stake in Zomedica Pharmaceuticals Corp. (AMEX:ZOM). The institutional investor has increased its shareholding in the Healthcare company by 126.29% to 15.32 million shares with purchase of 8.55 million shares. This fresh investment now brings its stake to 2.72% valued currently at $2.42 million. In addition, Millennium Management LLC raised its holdings by 0.98 million to 0.98 million shares.
With over 40.88 million Zomedica Pharmaceuticals Corp. (ZOM) shares trading Monday and a closing price of $0.11 on the day, the dollar volume was approximately $4.5 million. The shares have shown a negative weekly performance of -12.69% and its price on 08/31/20 lost nearly -9.19%. Currently, there are 564.05M common shares owned by the public and among those 510.05M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for ZOM have a consensus price objective of $0.50. The analysts have set the share’s price value over the next 12 months at a high of $0.50 and a low of $0.50 should the stock experience a downside. Incidentally, analysts’ outlook for the Zomedica Pharmaceuticals Corp. stock is 2.00 for the next 12 months. But an upside of 78.0% will see the stock hit the forecast high price target while mean target price for the stock is $0.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Zomedica Pharmaceuticals Corp. are Vanguard Total Stock Market Index, USAA Extended Market Index Fund, and Gabelli Equity Trust. Vanguard Total Stock Market Index owns 7.96 million shares of the company’s stock, all valued at over $1.26 million. USAA Extended Market Index Fund bought 19861.0 shares to see its total holdings expand to 31916.0 shares valued at over $5043.0 and representing 0.01% of the shares outstanding. Gabelli Equity Trust now owns shares totaling to 0.00% of the shares outstanding.
Shares of Zomedica Pharmaceuticals Corp. (AMEX: ZOM) opened at $0.12, unchanged from a prior closing price of $0.12. However, the script later closed the day at $0.11, down -9.19%. The company’s stock has a 5-day price change of -12.69% and -32.90% over the past three months. ZOM shares are trading -67.16% year to date (YTD), with the 12-month market performance down to -70.45% lower. It has a 12-month low price of $0.11 and touched a high of $0.50 over the same period. Currently, 40.88 million shares have been traded, compared to an average intraday trading volume of 55.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -22.86%, -34.55%, and -50.82% respectively.
Institutional ownership of Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares accounts for 6.40% of the company’s 564.05M shares outstanding. Mutual fund holders own 5.72%, while other institutional holders and individual stakeholders account for 9.51% and 1.42% respectively.
It has a market capitalization of $63.32M and a beta (3y monthly) value of -0.20. The earnings-per-share (ttm) stands at -$0.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.72% over the week and 5.87% over the month.
Analysts forecast that Zomedica Pharmaceuticals Corp. (ZOM) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$0.02 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.02 a year ago. Earnings per share for the fiscal year are expected to decrease by -4.50%, and 33.30% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Zomedica Pharmaceuticals Corp. (ZOM) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”